LAG3 and melanoma: At present, several clinical phase II and III studies investigate LAG3 targeting agents (e.g. relatlimab, Bristol Myers Squibb, New York City, NY, USA), as well as ideal therapeutic sequences and combinations of LAG3 antibodies with agents targeting PD-1 and CTLA-4 in several malignancies including melanoma.